Petra Pharma Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • M&A

Petra Pharma General Information

Description

Developer of phosphoinositide (PI) signaling pathways intended to treat cancer and metabolic diseases. The company develops small molecules to target cellular processes to therapeutically impact human health including cell division, growth, trafficking and signaling, enabling doctors to access novel drugs that may help them treat their patients

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 450 East 29th Street
  • Suite 506
  • New York, NY 10016
  • United States
+1 (646)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Acquirer
Vertical(s)
Corporate Office
  • 450 East 29th Street
  • Suite 506
  • New York, NY 10016
  • United States
+1 (646)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Petra Pharma Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Merger/Acquisition 14-May-2020 Completed Generating Revenue
2. Early Stage VC 31-Mar-2020 Completed Generating Revenue
1. Early Stage VC (Series A) 06-Jan-2016 $48M $48M Completed Startup
To view Petra Pharma’s complete valuation and funding history, request access »

Petra Pharma Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A
To view Petra Pharma’s complete cap table history, request access »

Petra Pharma Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of phosphoinositide (PI) signaling pathways intended to treat cancer and metabolic diseases. The company devel
Drug Discovery
New York, NY

Madison, WI
 

Oberdorf, Switzerland
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Petra Pharma Competitors (77)

One of Petra Pharma’s 77 competitors is Centrose, a Venture Capital-Backed company based in Madison, WI.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Centrose Venture Capital-Backed Madison, WI
Unicyte Venture Capital-Backed Oberdorf, Switzerland
NGM Biopharmaceuticals Private Equity-Backed South San Francisco, CA
Iovance Biotherapeutics Corporation San Carlos, CA
Akero Therapeutics Corporate Backed or Acquired South San Francisco, CA
You’re viewing 5 of 77 competitors. Get the full list »

Petra Pharma Patents

Petra Pharma Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2025231052-A1 Solid dispersions of 6-chloro-3-[(1r)-1-[3,6-dimethyl-2-(2- methylindazol-5-yl)-4-oxo-chromen-8-yl]ethoxy]pyridine-2-carboxamide Pending 01-May-2024
WO-2025231053-A1 Solid forms of 6-chloro-3-[(1r)-1-[3,6-dimethyl-2-(2-methylindazol-5-yl)-4-oxo-chromen-8-yl]ethoxy]pyridine-2-carboxamide Pending 01-May-2024
WO-2025221919-A1 (r)-3-(6-chloro-3-((1-(2-cyclopropyl-6-fluoro-3-methyl-4-oxo-4h-chromen-8-yl)ethyl)amino)pyridin-2-yl)-1,2,4-oxadiazol-5(4h)-one as pi3k inhibitor for the treatment of cancer Pending 17-Apr-2024
AU-2023373670-A1 Allosteric chromenone inhibitors of phosphoinositide 3-kinase (pi3k) for the treatment of disease Pending 02-Nov-2022
AU-2023373671-A1 Allosteric chromenone inhibitors of phosphoinositide 3-kinase (pi3k) for the treatment of disease Pending 02-Nov-2022 A61K31/352
To view Petra Pharma’s complete patent history, request access »

Petra Pharma Former Investors (13)

Investor Name Investor Type Holding Investor Since Participating Rounds
180 Degree Capital Hedge Fund Minority
ARCH Venture Partners Venture Capital Minority
AbbVie Ventures Corporate Venture Capital Minority
Accelerator Life Science Partners Venture Capital Minority
Alexandria Venture Investments Venture Capital Minority
You’re viewing 5 of 13 investors. Get the full list »

Petra Pharma FAQs

  • When was Petra Pharma founded?

    Petra Pharma was founded in 2015.

  • Where is Petra Pharma headquartered?

    Petra Pharma is headquartered in New York, NY.

  • What industry is Petra Pharma in?

    Petra Pharma’s primary industry is Drug Discovery.

  • Is Petra Pharma a private or public company?

    Petra Pharma is a Private company.

  • What is Petra Pharma’s current revenue?

    The current revenue for Petra Pharma is .

  • How much funding has Petra Pharma raised over time?

    Petra Pharma has raised $75.5M.

  • Who are Petra Pharma’s investors?

    180 Degree Capital, ARCH Venture Partners, AbbVie Ventures, Accelerator Life Science Partners, and Alexandria Venture Investments are 5 of 13 investors who have invested in Petra Pharma.

  • Who are Petra Pharma’s competitors?

    Centrose, Unicyte, NGM Biopharmaceuticals, Iovance Biotherapeutics, and Akero Therapeutics are some of the 77 competitors of Petra Pharma.

  • When was Petra Pharma acquired?

    Petra Pharma was acquired on 14-May-2020.

  • Who acquired Petra Pharma?

    Petra Pharma was acquired by Lilly USA.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process